Lazard Asset Management
ARQT icon

Lazard Asset Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Lazard Asset Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.49M Sell
133,146
-21,420
-14% -$499K 0.01% 744
2026
Q1 		$3.64M Buy
154,566
+61,212
+66% +$1.56M 0.01% 665
2025
Q4 		$2.71M Sell
93,354
-186,265
-67% -$4.77M ﹤0.01% 748
2025
Q3 		$5.27M Sell
279,619
-106,392
-28% -$1.68M 0.01% 569
2025
Q2 		$5.41M Buy
386,011
+11,928
+3% +$167K 0.01% 711
2025
Q1 		$5.85M Sell
374,083
-14,230
-4% -$200K 0.01% 633
2024
Q4 		$5.41M Sell
388,313
-414,891
-52% -$4.55M 0.01% 622
2024
Q3 		$7.47M Buy
803,204
+443,207
+123% +$4.37M 0.01% 533
2024
Q2 		$3.35M Buy
+359,997
New +$3.26M ﹤0.01% 771

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Lazard Asset Management's ARQT Position: Q2 2026 in Review

Lazard Asset Management reduced its Arcutis Biotherapeutics (ARQT) stake by 14% in Q2 2026, selling an estimated $499K and leaving 133,146 shares worth $3.49M. The position accounts for 0.01% of the portfolio, ranked #744.

Lazard Asset Management first reported a position in ARQT in Q2 2024 and has held it in 9 quarters since. The position peaked at $7.47M in Q3 2024. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Lazard Asset Management held 133,146 shares of Arcutis Biotherapeutics worth $3.49M as of Q2 2026.
  • Lazard Asset Management sold 21,420 Arcutis Biotherapeutics shares in Q2 2026, an estimated $499K.
  • Arcutis Biotherapeutics made up 0.01% of Lazard Asset Management's portfolio in Q2 2026, its #744 holding.
  • Lazard Asset Management first reported a position in Arcutis Biotherapeutics in Q2 2024 and has held it in 9 quarters since.
  • Lazard Asset Management's Arcutis Biotherapeutics position peaked at $7.47M in Q3 2024.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Lazard Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.